MedPath

Effect of Recombinant Human Granulocyte Colony- Stimulating Factor on CD11b in Septic Neonates

Phase 4
Completed
Conditions
Neonatal Sepsis
Interventions
Drug: rh-GCSF
Registration Number
NCT01479114
Lead Sponsor
Ain Shams University
Brief Summary

The investigators aimed to evaluate the effect of G-CSF administration in septic neonates on neutrophil production and CD11b expression.

Detailed Description

Neonates are susceptible to septicemia secondary to quantitative and qualitative neutrophilic defects. Granulocyte-colony stimulating factor (G-CSF) stimulates myeloid progenitor cell proliferation and induces selective neutrophil functions.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
90
Inclusion Criteria
  • newborn infants with postnatal age < 28 day,
  • minimum gestational age of 28 weeks and requiring intensive care with clinical signs consistent with the diagnosis of neonatal sepsis,
  • with or without neutropenia
Read More
Exclusion Criteria
  • neonates with congenital malformation,
  • major chromosomal abnormalities,
  • prior use of cytokines or intravenous immunoglobulin, or decreased hemoglobin and/or hematocrit at or below the levels necessitate transfusion
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
G-CSF grouprh-GCSF-
Primary Outcome Measures
NameTimeMethod
all cause mortalityone month
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath